The study was conducted in treatment-naive patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Boehringer-Ingelheim-to-Announce-Pivotal-Phase-3-H/ArticleNewsFeed/Article/detail/810003?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Boehringer-Ingelheim-to-Announce-Pivotal-Phase-3-H/ArticleNewsFeed/Article/detail/810003?ref=25
No comments:
Post a Comment